| First Author | Kalinin S | Year | 2023 |
| Journal | Neurosci Lett | Volume | 815 |
| Pages | 137497 | PubMed ID | 37748675 |
| Mgi Jnum | J:341729 | Mgi Id | MGI:7538744 |
| Doi | 10.1016/j.neulet.2023.137497 | Citation | Kalinin S, et al. (2023) Astrocyte lipocalin-2 modestly effects disease severity in a mouse model of multiple sclerosis while reducing mature oligodendrocyte protein and mRNA expression. Neurosci Lett 815:137497 |
| abstractText | Roles for lipocalin-2 (LCN2, also referred to as neutrophil gelatinase associated lipocalin, NGAL) in the progression of disease in multiple sclerosis and its animal models have been reported; however, the importance of astrocyte-derived LCN2, a major source of LCN2, have not been defined. We found that clinical scores in experimental autoimmune encephalomyelitis (EAE) were modestly delayed in mice with conditional knockout of LCN2 from astrocytes, associated with a small decrease in astrocyte GFAP expression. Immunostaining and qPCR of spinal cord samples showed decreased oligodendrocyte proteolipid protein and transcription factor Olig2 expression, but no changes in PDGFRalpha expression. These results suggest astrocyte LCN2 contributes to early events in EAE and reduces damage to mature oligodendrocytes at later times. |
